BioStock: Positive outcome for Alligator Bioscience’s joint study with Scandion Oncology
A little more than a year has passed since Alligator Bioscience and Scandion Oncology announced the start of a joint project exploring the anti-tumour effect in chemotherapy-resistant tumours using mitazalimab and SCO-101 together with chemotherapy Folfirinox. The companies have now achieved a positive outcome of their preclinical study and concluded their collaboration.
Read the article about Alligator Bioscience at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/